May 29 |
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
|
May 9 |
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
|
May 3 |
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Apr 9 |
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
|
Apr 1 |
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
|
Mar 12 |
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
|
Mar 1 |
NewAmsterdam Pharma Full Year 2023 Earnings: Revenues Miss Expectations
|
Feb 28 |
NewAmsterdam Pharma reports FY results
|
Feb 28 |
NewAmsterdam Pharma Co NV (NAMS) Faces Net Loss in 2023 Despite Clinical Progress
|
Feb 28 |
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
|